Goldman Sachs
PRCT icon

Goldman Sachs’s Procept Biorobotics PRCT Stock Holding History

Goldman Sachs’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Buy
447,537
+145,493
+48% +$3.64M ﹤0.01% 3217
2026
Q1 		$7.55M Sell
302,044
-215,688
-42% -$6.08M ﹤0.01% 3308
2025
Q4 		$16.3M Buy
517,732
+241,863
+88% +$8.02M ﹤0.01% 2576
2025
Q3 		$9.85M Sell
275,869
-74,651
-21% -$3.41M ﹤0.01% 2984
2025
Q2 		$20.2M Sell
350,520
-59,903
-15% -$3.39M ﹤0.01% 2117
2025
Q1 		$23.9M Sell
410,423
-139,892
-25% -$9.55M ﹤0.01% 1858
2024
Q4 		$44.3M Buy
550,315
+195,380
+55% +$16.7M 0.01% 1410
2024
Q3 		$28.4M Buy
354,935
+74,972
+27% +$5.33M ﹤0.01% 1738
2024
Q2 		$17.1M Buy
279,963
+130,846
+88% +$7.78M ﹤0.01% 2009
2024
Q1 		$7.37M Buy
149,117
+52,890
+55% +$2.52M ﹤0.01% 2758
2023
Q4 		$4.03M Buy
96,227
+5,365
+6% +$183K ﹤0.01% 3347
2023
Q3 		$2.98M Buy
90,862
+11,059
+14% +$377K ﹤0.01% 3437
2023
Q2 		$2.82M Sell
79,803
-84,821
-52% -$2.8M ﹤0.01% 3605
2023
Q1 		$4.68M Buy
164,624
+38,002
+30% +$1.34M ﹤0.01% 3124
2022
Q4 		$5.26M Buy
126,622
+57,379
+83% +$2.46M ﹤0.01% 3119
2022
Q3 		$2.87M Buy
69,243
+53,973
+353% +$2.15M ﹤0.01% 3645
2022
Q2 		$499K Buy
15,270
+4,566
+43% +$166K ﹤0.01% 5076
2022
Q1 		$375K Buy
+10,704
New +$258K ﹤0.01% 5520
2021
Q4 		– Sell
-57,803
Closed -$2.21M – 6648
2021
Q3 		$2.21M Buy
+57,803
New +$2.22M ﹤0.01% 4108

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs's PRCT Position: Q2 2026 in Review

Goldman Sachs increased its Procept Biorobotics (PRCT) stake by 48% in Q2 2026, buying an estimated $3.64M and bringing the position to 447,537 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

Goldman Sachs first reported a position in PRCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $44.3M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Goldman Sachs held 447,537 shares of Procept Biorobotics worth $10.1M as of Q2 2026.
  • Goldman Sachs bought 145,493 Procept Biorobotics shares in Q2 2026, an estimated $3.64M.
  • Procept Biorobotics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3217 holding.
  • Goldman Sachs first reported a position in Procept Biorobotics in Q3 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Procept Biorobotics position peaked at $44.3M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.